To explore the therapeutic effects and immune function of Heluo Shugan tablets as an adjuvant treatment in patients with hepatitis B virus decompensated cirrhosis.
A total of 80 patients with hepatitis B virus decompensated cirrhosis admitted to our hospital from January 2022 to June 2024 were selected and divided into the control group and the observation group, with 40 cases in each group. The control group received conventional treatment, while the observation group was treated in combination with Heluo Shugan tablets. Both groups received continuous treatment for 6 months. The clinical efficacy, hepatitis B virus deoxyribonucleic acid(HBV-DNA) load, alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin(TBil), hyaluronic acid(HA), laminin(LN), procollagen type Ⅲ peptide(PC-Ⅲ), type Ⅳ collagen(Ⅳ-C), spleen thickness, inner diameter of portal vein, inner diameter of splenic vein, changes of cluster of differentiation antigen(CD)3+, CD4+, CD4+/CD8+, adverse reactions, complications and recompensatory conditions between the two groups were compared.
After treatment, the total effective rates of Western medicine treatment(95.00% vs. 62.50%) and traditional Chinese medicine treatment(92.50% vs. 70.00%) in the observation group were both higher than those in the control group, and the differences were significant(P<0.05). Compared with the control group, the HBV-DNA load, ALT, AST, TBil, HA, LN, PC-Ⅲ, Ⅳ-C, spleen thickness, portal vein inner diameter and splenic vein inner diameter in the observation group were all lower, and CD3+, CD4+, CD4+/CD8+ were all higher, with significant differences(P<0.05). There was no statistically significant difference in the incidence of adverse reactions and complications between the two groups(P>0.05). The follow-up was conducted until April 2025. The recompensation rate of the observation group was higher than that of the control group(37.84% vs. 16.67%), and the difference was significant(P<0.05).
The use of Heluo Shugan tablets in patients with hepatitis B virus decompensated cirrhosis has received good application feedback and has relatively good safety.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |